HOBOKEN, N.J. (July 16, 2018) – Octapharma USA was the exclusive sponsor of the VWD Connect Foundation Conference, a four-day national program for patients with Type 3/severe Von Willebrand Disease (VWD), recently held at the PGA...
Toronto, Canada, June 25, 2018: – Octapharma announced today the launch of the Canadian PREVAIL (Immune Tolerance Induction in Hemophilia A Patients using wilate®) study for patients with Hemophilia A. The PREVAIL study will...
Octapharma announces approval of new Nuwiq® product strengths in Europe, increasing dosing flexibility for patients with haemophilia A
Lachen, Switzerland 18 June 2018: Octapharma announced today that the European Medicines Agency (EMA) has approved an extension of marketing authorisation for its human cell line-derived recombinant factor VIII (rFVIII)...
Octapharma share promising preclinical data for SubQ-8, a novel subcutaneous recombinant FVIII, at WFH 2018
Lachen, Switzerland 28 May 2018: Octapharma announced today that pre-clinical data for SubQ-8 were presented during a symposium at the recent World Federation of Hemophilia (WFH) 2018 World Congress in Glasgow, UK. SubQ-8,...
Octapharma present new data on the benefits of Nuwiq® in patients with haemophilia A at the World Federation of Hemophilia 2018 World Congress
Lachen, Switzerland 28 May 2018: Octapharma announced today that new data on the benefits of Nuwiq® in patients with haemophilia A were presented during a symposium at the recent World Federation of Hemophilia (WFH) 2018 World...
Interested Camp Professionals Should Apply by May 30th for Grant Funded Program
Chris Bombardier, First Hemophiliac to Climb the Seven Summits, Joins Octapharma USA at HFA Annual Symposium in Cleveland
Mountain Climber Will Discuss Mount Everest Climb, Upcoming Documentary One-on-One With Visitors of Octapharma Booth